Cost, mostly. In a national survey of 440 US adults who had started and then stopped a GLP-1, cost led at 36.1%. Side effects followed at 33.3%, lack of insurance coverage at 28.2%, and reaching a weight goal at 26.1%. Two of the top three are about money rather than medicine. Four in five had stopped inside twelve months.
An Italian study of people offered self-pay liraglutide found that cost was a common reason to decline. The article on why patients declined liraglutide describes that decision before treatment began [2]. In a separate US analysis, the study of insurance and medication use found lower odds of use among uninsured adults than among those with private insurance (odds ratio 0.53). Its estimate combined GLP-1 receptor agonists and SGLT2 inhibitors [3]. A separate clinic study where medication was free found a median of 10.7 months on treatment [4]. Each study measures a different decision about starting or continuing medication.
This site exists to compare sellers of compounded GLP-1 drugs. The study below contains a finding about those sellers that does not flatter them, and about the category this site makes its money from. It is here because a comparison that omits the uncomfortable result is not a comparison.
Who was asked
Researchers screened 7,035 people and surveyed 440 US adults who had started and then stopped a GLP-1 receptor agonist [1]. Half were female, 42.3% were aged 18 to 34, and 23.8% had type 2 diabetes.
More than half — 54.6% — had stopped within six months of starting, and 79.7% within twelve among respondents who had already stopped. A separate study of how long patients stayed on treatment also found frequent discontinuation within a year. The two studies report different estimates.
Why they stopped
Cost was the most common reason at 36.1%, followed by side effects at 33.3%, lack of insurance coverage at 28.2%, and reaching a weight-loss goal at 26.1%. The GLP-1 monthly cost guide explains how to add care fees and account for refills when estimating what you would pay.
Respondents with diabetes were significantly likelier than those without to stop because of side effects — 50.1% against 28.1%. How people paid was unusual too. Some 31.3% first filled a prescription without insurance at all. Another 35.4% used a copayment coupon, 22.0% a free sample, and 14.4% got the drug from a friend or family member.
What could explain it
The survey did not establish which product or dose explained the difference. The review of published dose and pricing terms examines what sellers disclose about higher doses. The review is based on listings and does not measure patient outcomes.
What to do with it
When budgeting for ongoing treatment, use the billed-price guide to identify which charges repeat after the introductory offer. Across the 158 injectable semaglutide prices in our catalog, the median monthly rate was $186 as of November 2026. At that rate, 12 months would cost $2,232.
Ask the provider what your prescribed dose would cost and whether a dose change would affect your next bill.